skip to main content
OSTI.GOV title logo U.S. Department of Energy
Office of Scientific and Technical Information

Title: Identification of potent anticancer activity in Ximenia americana aqueous extracts used by African traditional medicine

Abstract

The antineoplastic activity of a plant powder used in African traditional medicine for treating cancer was investigated by analyzing the activity of various extracts in vitro. The most active, aqueous extract was subsequently subjected to a detailed investigation in a panel of 17 tumor cell lines, showing an average IC{sub 5} of 49 mg raw powder/ml medium. The sensitivity of the cell lines varied by two orders of magnitude, from 1.7 mg/ml in MCF7 breast cancer cells to 170 mg/ml in AR230 chronic-myeloid leukemia cells. Immortalized, non-tumorigenic cell lines showed a marginal sensitivity. In addition, kinetic and recovery experiments performed in MCF7 and U87-MG cells and a comparison with the antineoplastic activity of miltefosine, gemcitabine, and cisplatinum in MCF7, U87-MG, HEp2, and SAOS2 cells revealed no obvious similarity between the sensitivity profiles of the extract and the three standard agents, suggesting a different mechanism of cytotoxicity. The in vivo antitumor activity was determined in the CC531 colorectal cancer rat model. Significant anticancer activity was found following administration of equitoxic doses of 100 (perorally) and 5 (intraperitoneally) mg raw powder/kg, indicating a 95% reduced activity following intestinal absorption. By sequencing the mitochondrial gene for the large subunit of the ribulose bis-phosphatemore » carboxylase (rbcL) in DNA from the plant material, the source plant was identified as Ximenia americana. A physicochemical characterization showed that the active antineoplastic component(s) of the plant material are proteins with galactose affinity. Moreover, by mass spectrometry, one of these proteins was shown to contain a stretch of 11 amino acids identical to a tryptic peptide from the ribosome-inactivating protein ricin.« less

Authors:
 [1];  [1];  [2]
  1. Unit of Toxicology and Chemotherapy, Deutsches Krebsforschungszentrum Heidelberg, E100, Im Neuenheimer Feld 280, 69120 Heidelberg (Germany)
  2. Unit of Toxicology and Chemotherapy, Deutsches Krebsforschungszentrum Heidelberg, E100, Im Neuenheimer Feld 280, 69120 Heidelberg (Germany). E-mail: m.berger@dkfz.de
Publication Date:
OSTI Identifier:
20783441
Resource Type:
Journal Article
Resource Relation:
Journal Name: Toxicology and Applied Pharmacology; Journal Volume: 211; Journal Issue: 3; Other Information: DOI: 10.1016/j.taap.2005.05.016; PII: S0041-008X(05)00366-2; Copyright (c) 2005 Elsevier Science B.V., Amsterdam, The Netherlands, All rights reserved; Country of input: International Atomic Energy Agency (IAEA)
Country of Publication:
United States
Language:
English
Subject:
60 APPLIED LIFE SCIENCES; AMINO ACIDS; BROMIDES; CARBOXYLASE; DRUGS; GALACTOSE; IN VITRO; IN VIVO; INTESTINAL ABSORPTION; MAMMARY GLANDS; MASS SPECTROSCOPY; MYELOID LEUKEMIA; PEPTIDES; PHOSPHATES; PLANT GROWTH; PLANTS; RATS; RIBULOSE; RUBIDIUM CHLORIDES; SENSITIVITY; TETRAZOLIUM; TOXICITY; TUMOR CELLS

Citation Formats

Voss, Cristina, Eyol, Erguel, and Berger, Martin R. Identification of potent anticancer activity in Ximenia americana aqueous extracts used by African traditional medicine. United States: N. p., 2006. Web. doi:10.1016/j.taap.2005.05.016.
Voss, Cristina, Eyol, Erguel, & Berger, Martin R. Identification of potent anticancer activity in Ximenia americana aqueous extracts used by African traditional medicine. United States. doi:10.1016/j.taap.2005.05.016.
Voss, Cristina, Eyol, Erguel, and Berger, Martin R. Wed . "Identification of potent anticancer activity in Ximenia americana aqueous extracts used by African traditional medicine". United States. doi:10.1016/j.taap.2005.05.016.
@article{osti_20783441,
title = {Identification of potent anticancer activity in Ximenia americana aqueous extracts used by African traditional medicine},
author = {Voss, Cristina and Eyol, Erguel and Berger, Martin R.},
abstractNote = {The antineoplastic activity of a plant powder used in African traditional medicine for treating cancer was investigated by analyzing the activity of various extracts in vitro. The most active, aqueous extract was subsequently subjected to a detailed investigation in a panel of 17 tumor cell lines, showing an average IC{sub 5} of 49 mg raw powder/ml medium. The sensitivity of the cell lines varied by two orders of magnitude, from 1.7 mg/ml in MCF7 breast cancer cells to 170 mg/ml in AR230 chronic-myeloid leukemia cells. Immortalized, non-tumorigenic cell lines showed a marginal sensitivity. In addition, kinetic and recovery experiments performed in MCF7 and U87-MG cells and a comparison with the antineoplastic activity of miltefosine, gemcitabine, and cisplatinum in MCF7, U87-MG, HEp2, and SAOS2 cells revealed no obvious similarity between the sensitivity profiles of the extract and the three standard agents, suggesting a different mechanism of cytotoxicity. The in vivo antitumor activity was determined in the CC531 colorectal cancer rat model. Significant anticancer activity was found following administration of equitoxic doses of 100 (perorally) and 5 (intraperitoneally) mg raw powder/kg, indicating a 95% reduced activity following intestinal absorption. By sequencing the mitochondrial gene for the large subunit of the ribulose bis-phosphate carboxylase (rbcL) in DNA from the plant material, the source plant was identified as Ximenia americana. A physicochemical characterization showed that the active antineoplastic component(s) of the plant material are proteins with galactose affinity. Moreover, by mass spectrometry, one of these proteins was shown to contain a stretch of 11 amino acids identical to a tryptic peptide from the ribosome-inactivating protein ricin.},
doi = {10.1016/j.taap.2005.05.016},
journal = {Toxicology and Applied Pharmacology},
number = 3,
volume = 211,
place = {United States},
year = {Wed Mar 15 00:00:00 EST 2006},
month = {Wed Mar 15 00:00:00 EST 2006}
}